Tara Bancroft
Stock Analyst at TD Cowen
(4.81)
# 494
Out of 4,600 analysts
279
Total ratings
48.9%
Success rate
27.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tara Bancroft
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TGTX TG Therapeutics | Maintained: Buy | $75 | $46.41 | +61.60% | 14 | Aug 3, 2026 | |
| LNTH Lantheus Holdings | Downgraded: Hold | $110 → $103 | $100.95 | +1.54% | 21 | Aug 3, 2026 | |
| OCUL Ocular Therapeutix | Maintained: Buy | $20 | $8.64 | +131.48% | 24 | Aug 3, 2026 | |
| BCYC Bicycle Therapeutics | Maintained: Buy | n/a | $3.96 | - | 13 | Jul 30, 2026 | |
| IRON Disc Medicine | Maintained: Buy | n/a | $77.90 | - | 14 | Jul 30, 2026 | |
| PTGX Protagonist Therapeutics | Maintained: Buy | $100 → $155 | $134.53 | +15.22% | 16 | Jul 20, 2026 | |
| URGN UroGen Pharma | Maintained: Buy | $35 → $50 | $39.77 | +25.72% | 23 | Jul 20, 2026 | |
| KLRS Kalaris Therapeutics | Initiated Coverage: Buy | n/a | $4.28 | - | 1 | Jun 15, 2026 | |
| CELC Celcuity | Maintained: Buy | n/a | $92.33 | - | 13 | May 14, 2026 | |
| STRO Sutro Biopharma | Maintained: Buy | n/a | $25.72 | - | 12 | May 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $2.60 | - | 13 | May 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $20.15 | - | 12 | May 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $3.49 | - | 2 | May 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $4.15 | - | 12 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $3 | $1.35 | +123.05% | 19 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20 | $12.02 | +66.39% | 2 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $75 | $55.04 | +36.26% | 15 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $26.17 | - | 2 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $39.50 | - | 3 | Apr 1, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $0.7356 | - | 11 | Mar 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.91 | - | 14 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20.00 | $14.41 | +38.79% | 16 | Feb 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.38 | n/a | 2 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | n/a | $5.76 | n/a | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $15.51 | n/a | 2 | Jul 26, 2024 |
TG Therapeutics
Aug 3, 2026
Maintained: Buy
Price Target: $75
Current: $46.41
Upside: +61.60%
Lantheus Holdings
Aug 3, 2026
Downgraded: Hold
Price Target: $110 → $103
Current: $100.95
Upside: +1.54%
Ocular Therapeutix
Aug 3, 2026
Maintained: Buy
Price Target: $20
Current: $8.64
Upside: +131.48%
Bicycle Therapeutics
Jul 30, 2026
Maintained: Buy
Price Target: n/a
Current: $3.96
Upside: -
Disc Medicine
Jul 30, 2026
Maintained: Buy
Price Target: n/a
Current: $77.90
Upside: -
Protagonist Therapeutics
Jul 20, 2026
Maintained: Buy
Price Target: $100 → $155
Current: $134.53
Upside: +15.22%
UroGen Pharma
Jul 20, 2026
Maintained: Buy
Price Target: $35 → $50
Current: $39.77
Upside: +25.72%
Kalaris Therapeutics
Jun 15, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $4.28
Upside: -
Celcuity
May 14, 2026
Maintained: Buy
Price Target: n/a
Current: $92.33
Upside: -
Sutro Biopharma
May 14, 2026
Maintained: Buy
Price Target: n/a
Current: $25.72
Upside: -
May 13, 2026
Maintained: Hold
Price Target: n/a
Current: $2.60
Upside: -
May 11, 2026
Maintained: Buy
Price Target: n/a
Current: $20.15
Upside: -
May 10, 2026
Maintained: Hold
Price Target: n/a
Current: $3.49
Upside: -
May 7, 2026
Maintained: Hold
Price Target: n/a
Current: $4.15
Upside: -
May 6, 2026
Maintained: Buy
Price Target: $3
Current: $1.35
Upside: +123.05%
May 6, 2026
Maintained: Buy
Price Target: $20
Current: $12.02
Upside: +66.39%
May 6, 2026
Maintained: Buy
Price Target: $75
Current: $55.04
Upside: +36.26%
May 6, 2026
Maintained: Buy
Price Target: n/a
Current: $26.17
Upside: -
Apr 1, 2026
Maintained: Buy
Price Target: n/a
Current: $39.50
Upside: -
Mar 11, 2026
Maintained: Buy
Price Target: n/a
Current: $0.7356
Upside: -
Mar 10, 2026
Rated: Hold
Price Target: n/a
Current: $3.91
Upside: -
Feb 19, 2026
Maintained: Buy
Price Target: $20.00
Current: $14.41
Upside: +38.79%
Mar 14, 2025
Rated: Hold
Price Target: n/a
Current: $1.38
Upside: n/a
Aug 9, 2024
Rated: Buy
Price Target: n/a
Current: $5.76
Upside: n/a
Jul 26, 2024
Downgraded: Hold
Price Target: n/a
Current: $15.51
Upside: n/a